Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 5/20 | 0.45 |
| ▸ | CCND1 | P24385 | 5/20 | 0.45 |
| ▸ | CCND2 | P30279 | 4/20 | 0.45 |
| ▸ | CCND3 | P30281 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285709 | 0.92 | HTR1A (0.46) | JAK2PTK2JAK3MAPK1KDM4E | |
| SCHEMBL16285706 | 0.91 | CDK4 (0.48) | JAK2PTK2JAK3MAPTALOX15 | |
| SCHEMBL16285702 | 0.90 | BRD4 (0.45) | JAK2PTK2JAK3MAPTTSHR | |
| SCHEMBL16286127 | 0.89 | CDK4 (0.42) | JAK2PTK2JAK3TDP1CDK4 | |
| SCHEMBL16286122 | 0.89 | FGFR4 (0.44) | JAK2PTK2JAK3CDK4CCND1 | |
| SCHEMBL16285672 | 0.87 | CCND3 (0.47) | JAK2JAK3TSHRKDM4EALOX15 | |
| SCHEMBL16285692 | 0.87 | CDK4 (0.46) | MAPTKDM4EALDH1A1GAACDK4 | |
| SCHEMBL16285699 | 0.87 | CDK4 (0.46) | JAK2PTK2JAK3MAPTTSHR | |
| SCHEMBL16285713 | 0.87 | CDK4 (0.46) | JAK2JAK3TSHRTDP1CDK4 | |
| SCHEMBL16285704 | 0.85 | CDK4 (0.42) | JAK2JAK3MAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | JAK2 3533/4885PTK2 476/4885JAK3 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.